Vaxcyte Achieves Major Milestone: OPUS-1 and OPUS-2 Phase 3 Trials for VAX-31 Fully Enrolled, Setting Stage for New Vaccine Standard
Two Key Clinical Trials Reach Full Enrollment: A Turning Point for Pneumococcal Disease Prevention
Vaxcyte (NASDAQ:PCVX) has successfully completed enrollment in its OPUS-1 and OPUS-2 Phase 3 trials, bringing its 31-valent pneumococcal conjugate vaccine (VAX-31) another step closer to redefining standards for adult and pediatric protection against invasive pneumococcal disease (IPD) and pneumonia. With approximately 4,000 adults enrolled for OPUS-1 and 1,300 for OPUS-2, Vaxcyte is now positioned to deliver pivotal safety, tolerability, and immunogenicity data as soon as Q4 2026 and the first half of 2027.
VAX-31 Poised to Set a New Immunization Benchmark, Expanding Disease Coverage by Up to 34% Over Existing Vaccines
Unlike earlier pneumococcal vaccines, VAX-31 is crafted to protect against 31 distinct serotypes—the broadest spectrum in the clinic. In adults aged 50 and above, VAX-31 is designed to cover approximately 95% of IPD and up to 88% of pneumococcal pneumonia cases. This could translate to an incremental 14-34% increase in IPD coverage and 19-31% increase for pneumonia over current options.
| VAX-31 Coverage (Adults =50y) | Current Standard | Incremental Gain |
|---|---|---|
| ~95% IPD | Up to 81% | 14% – 34% |
| ~88% Pneumococcal Pneumonia | Up to 69% | 19% – 31% |
For children, VAX-31 is targeting up to 92% coverage for IPD and 96% for acute otitis media due to Streptococcus pneumoniae, outpacing currently available pediatric vaccines and potentially offering a 23-44% and 35-62% incremental gain, respectively.
OPUS-1: Head-to-Head Against Industry Leaders and Focused on Superiority for Unique Serotypes
OPUS-1, the adult pivotal trial, is a randomized, double-blind, active-controlled study comparing VAX-31 against Capvaxive® (PCV21) and Prevnar 20® (PCV20). Top goals are to demonstrate noninferiority for the 28 shared serotypes and superiority for three serotypes unique to VAX-31 (2, 7C, 20C), plus serotype 20B.
| Primary Immunogenicity Goals | Superiority Targets |
|---|---|
| Noninferiority for 28 serotypes (CI LB >0.667) | Serotypes 2, 7C, 20C, 20B (CI LB >2.0) |
Results from this trial will determine if VAX-31 can meet or exceed the immune responses produced by established vaccines, especially for serotypes where competitors fall short.
OPUS-2 Study Designed for Real-World Insights with Influenza Vaccine Co-Administration
OPUS-2 investigates the safety and immune response of VAX-31 when given at the same time as or one month apart from a licensed flu shot. This approach reflects real-world vaccination scenarios and is critical for post-approval integration into adult immunization schedules. Data are expected in the first half of 2027.
Potential Regulatory Tailwinds: Breakthrough Therapy Designation Extended by FDA
VAX-31's clinical program proceeds with regulatory momentum. In May 2025, the FDA broadened its Breakthrough Therapy designation to include prevention of pneumonia—not just IPD—underscoring confidence in VAX-31’s Phase 1/2 results: robust immunogenicity and safety that matched or surpassed PCV20 across all tested serotypes.
The Bottom Line: VAX-31 Could Redefine Vaccine Coverage for Adults and Children
With broad serotype coverage, demonstrated immunogenicity, and a robust clinical program aligned with the FDA, VAX-31 is now in the home stretch towards a potential Biologics License Application. Milestones in the next two years, including key data readouts, could confirm Vaxcyte’s ambition to set a new standard-of-care in preventing pneumococcal disease and pneumonia.
The story now pivots to the upcoming trial results: if VAX-31 meets its clinical objectives, current vaccine paradigms for both adults and children may quickly shift. Investors and healthcare professionals will be watching closely.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI